Medivive review

Medivive says longevity protocols start with baseline labs and follow-up monitoring, and names NAD⁺ by subcutaneous injection or IV. Its TRT page names intramuscular, transdermal cream and sublingual formats as possibilities, subject to a provider’s protocol; it does not identify a selected testosterone formulation. No NAD⁺ or TRT amount appears on the public pages. The homepage says there is no membership fee and a personalized price appears when a provider matches your protocol, while the terms describe renewable subscriptions. Lab inclusion and the first debit remain unknown.

Medivive is a US telehealth service running several programs on one account: compounded GLP-1 weight loss, testosterone replacement therapy for men, hormone replacement therapy for women, sexual health, hair, at-home lab testing, and a longevity program. The longevity page organizes protocols into four families (tissue repair, cognitive performance, metabolic and a cellular longevity stack) and names one compound individually, NAD⁺, given by subcutaneous injection or IV; the peptides in the other families are described by purpose rather than by name. Clinical care is provided by TrueEval Medical Group PLLC, which the site describes as a telehealth medical group operating in all 50 states, and the footer lists Medivive Health with a Sheridan, Wyoming address. It states that no insurance is accepted, that medication is compounded by a licensed US pharmacy, and that care is available in English and Spanish.

An AI assistant starts the intake and proposes a candidate protocol before a licensed provider reviews it. Medivive says longevity care begins with a baseline panel, a 90-day re-check and quarterly monitoring; TRT begins with a full endocrine panel. TrueEval Medical Group is named, along with lead clinician Shannon M. Smith. The company claims provider coverage across all 50 states, while terms restrict service to states where it operates; availability of any product or route is not enumerated. It describes an unnamed licensed 503A pharmacy. Terms say consultation fees are nonrefundable after clinician review and shipped medications cannot be refunded; cancellation is available through an account or support, with no stated advance deadline.

No NAD⁺ or TRT amount appears on the public product pages. The homepage says there is no membership fee and the personalized price is shown when a provider matches a protocol. It does not establish that baseline or follow-up labs are inside that amount, or publish the NAD⁺ dose, supply, IV administration charge, first debit or renewal charge. Terms say subscriptions renew unless canceled and assert current prices are on the website, despite no NAD⁺ amount in the checked pages. Ask for itemized medication, lab, administration and shipping charges and the renewal cadence before committing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Medivive states that its longevity compounds are prepared by a licensed 503A pharmacy, are not FDA-approved finished drug products and are not reviewed by the FDA for safety or efficacy, but it does not name the pharmacy, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, injected NAD⁺ has no controlled human outcome trials; the one human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which reliably raise blood NAD⁺, a biomarker rather than a clinical outcome. The site itself says the evidence base is still developing, which is the right frame. The tissue-repair and cognitive peptides are not named, so their evidence cannot be assessed from the public site; ask which compound you would receive. Testosterone replacement, on the other side of the service, is the one therapy here with a large randomized safety base, and it suppresses natural production and fertility and requires ongoing monitoring. Individual results vary.